What Gilead's latest 10-Q says: 5 signals
Gilead filed its latest 10-Q with the SEC on Aug 6, 2026. It discusses chief medical officer change, compliance burden and debt refinancing.
Public (GILD)Biotechnology Research10,000+ employeesgilead.comLinkedIn
- Filed
- Aug 6, 2026
- Filings
- 2
- Signals
- 8
10-Q · latest 8
What Gilead's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 5 signals
Gilead highlights recent appointment of Chief Medical Officer Dietmar Berger.
The company filed an offer letter for Dietmar Berger, indicating a key addition to the clinical leadership team.
Wells Fargo, National AssociationComputershare Trust Company, National Association
The filing of a severance agreement for Deborah Telman (former General Counsel) points to a recent major change in the legal department's leadership.
Wells Fargo, National AssociationComputershare Trust Company, National Association
Gilead faces tax examinations and disputes with IRS and authorities in Germany & Ireland.
The company is under examination by the U.S.
Gilead executes capital restructuring with new debt issuance and a $6B stock buyback authorization.
Gilead issued new senior notes in May 2026 and has over $6 billion remaining in its stock repurchase authorization as of June 2026.
$6B
Approximate dollar value of shares that may yet be purchased under stock repurchase programs.
Wells FargoComputershare Trust Company
Gilead issued multiple new series of senior notes in May 2026, indicating a recent capital raise.
The company entered into a new indenture agreement on May 20, 2026, to issue four new series of senior notes (due 2028, 2029, 2031, 2034).
Computershare Trust Company, National AssociationWells Fargo Bank, National Association
- SEC EDGAR
10-Q
Filed · 3 signals
The recent merger agreement with Arcellx, Inc.
Gilead announces merger agreement with Arcellx dated February 22, 2026
Gilead is expanding its portfolio by acquiring Arcellx.
Wells FargoComputershare Trust Company
Gilead ties 2026 executive pay to 'Adjusted EPS Growth Goals', increasing pressure on profitability.
A new performance share agreement makes Adjusted EPS a key metric for executive compensation starting in 2026.
Earnings calls
Gilead earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Facing complex logistics and reimbursement hurdles for new Yeztugo launch.The launch of the new injectable drug, Yeztugo, involves navigating complex payer coverage, reimbursement processes, and logistical challenges like "white bagging," creating a need for solutions that streamline patient journey management and provider integration. | |
| Raised full-year revenue guidance, citing strong HIV portfolio performanceThe company increased its full-year HIV revenue growth guidance from 3% to 5% and raised the low end of its total product sales range. This financial outperformance and confidence indicates strong cash flow and budget availability for strategic initiatives. | |
| Achieved record market share for key HIV drugs Biktarvy and DescovyFlagship HIV products Biktarvy and Descovy for PrEP reached record market shares of 52% and 45% respectively. This strong commercial momentum creates a need for investment in sales enablement, marketing automation, and data analytics to defend and expand this leadership position. | |
| Struggling to lower hurdles for community adoption of cell therapies.Despite expanding treatment centers, the company acknowledges that 'we have more to do' to lower barriers for community adoption of its complex cell therapies. This indicates a need for solutions related to provider education, patient logistics, and simplifying treatment workflows. | |
| Emphasizing disciplined operating expense management and business model leverage.Leadership repeatedly highlighted 'disciplined operating expense management' and 'operating expense discipline' as key contributors to financial performance. This signals a strong corporate mandate and appetite for technologies and services that can drive efficiency and reduce costs. | |
| New liver disease drug Livdelzi achieved 35% sequential growthThe liver disease drug Livdelzi grew 35% sequentially, surpassing $100 million in quarterly sales for the first time. This rapid growth in a new franchise indicates strong market uptake and creates budget opportunities for solutions that can support and scale this high-performing product line. |
Signal API · MCP
Track Gilead with the Signal API
One POST /v1/companies/enrich call with gilead.com returns Gilead 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"gilead.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Gilead 10-Q
When did Gilead file its latest 10-Q?
What did Gilead disclose in its latest 10-Q?
What did Gilead say on its recent earnings calls?
Where can I read Gilead's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .